Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China flag China · Delayed Price · Currency is CNY
60.33
-0.70 (-1.15%)
At close: Dec 26, 2025
180.21%
Market Cap37.21B
Revenue (ttm)1.37B
Net Income (ttm)870.39M
Shares Out616.79M
EPS (ttm)1.39
PE Ratio43.36
Forward PE121.47
Dividend0.12 (0.20%)
Ex-Dividend DateNov 7, 2025
Volume2,598,771
Average Volume3,246,113
Open60.50
Previous Close61.03
Day's Range60.30 - 61.50
52-Week Range19.82 - 83.00
Beta0.88
RSI44.07
Earnings DateMar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 995
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688336
Full Company Profile

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.

Financial Statements

News

There is no news available yet.